Alnylam Pharmaceuticals, Inc. (0HD2.L) LSE

455.05

+6.35(+1.42%)

Updated at September 08 02:30PM

Currency In USD

Alnylam Pharmaceuticals, Inc.

Address

675 West Kendall Street

Cambridge, MA 02142

United States of America

Phone

617 551 8200

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

2230

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Dr. Yvonne L. Greenstreet M.B.A., M.D.Chief Executive Officer & Director4.25M1963
Dr. Phillip A. Sharp Ph.D.Co-Founder, Member of the Scientific Advisory Board & Independent Director105,0001945
Dr. Kevin Joseph Fitzgerald Ph.D.Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development1.23M1968
Mr. Tolga Tanguler M.B.A.Executive Vice President & Chief Commercial Officer1.31M1973
Dr. Pushkal P. Garg M.D.Chief Medical Officer and Executive Vice President of Development & Medical Affairs1.42M1968
Mr. Jeffrey V. Poulton M.B.A.Chief Financial Officer & Executive Vice President1.43M1968
Mr. Timothy J. MainesChief Technical Operations & Quality Officer0N/A
Ms. Christine Regan LindenboomChief Corporate Communications Officer01982
Mr. Piyush Sharma J.D.Chief Ethics & Compliance Officer0N/A
Mr. Robert W. Hesslein Esq., J.D.Executive Vice President, Chief Legal Officer & Corporate Secretary01953

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.